Gynecological Cancer Trials

Gynecologic Oncology

Trials are listed from Phase 1 to Phase 3, alphabetically.  Please click on the name of the Lead Clinical Research Coordinator (CRC) to request more information about each trial.

Protocol ID

Official Title

PI Name

Lead CRC

Disease Site


TESARO 4010-01-001   NCT0275284 Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors S. Ghamande Ashlyn Stevenson Advanced solid tumors I
NRG-GY007  NCT02713386 A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Protocol Type: Treatment S. Ghamande Melissa James Ovarian, Fallopian Tube, or Peritoneal Cancer I/II
GCT1015-05-ENGOT-CX8  NCT03786081 A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer S. Ghamande Katie Dorr Cervical Cancer Ib/II
GOG-3028/C-750-01  NCT03894215 A Two-arm, Randomized, Non-comparative, Phase 2 Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS S. Ghamande Melissa James Cervical Cancer II
Inovio HPV-201  NCT03180684 A Phase 2, Randomized, Open Label, Efficacy Study of VGX-3100 Delivered Intramuscularly Followed by Electroporation With CELLECTRA® 2000 Alone or in Combination With Imiquimod, for the Treatment of HPV-16 and/or HPV-18 Related High Grade Squamous lntraepithelial Lesion (HSIL) of the Vulva Protocol D. Ferris Angela Goebel HPV Related HIgh Grade Squamous Intraepithelia Lesion (HSIL) II
LION C-145-04  NCT03108495 A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma S. Ghamande Katie Dorr Cervical Cancer II
NRG-GY006 NCT02466971 
A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer S. Ghamande  Melissa James Uterine Cervical or Vaginal Cancer II
NRG-GY017  NCT03738228 Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer S. Ghamande Melissa James Cervical Cancer II
SGNTV-002  NCT03657043 Open Label Phase 2 Study of Tisotumab Vedotin for Patients with Platinum-Resistant Ovarian Cancer with a Safety Run-in of a Dose-Dense Regimen S. Ghamande Donna Wheatley Ovarian Cancer II
NRG-GY009 NCT02839707 A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer S. Ghamande Melissa James Ovarian Cancer II/III

GOG-0213 NCT00565851

A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) Protocol S. Ghamande Donna Wheatley Ovarian, Primary Peritoneal, and Fallopian Tube Cancer III
MK7902-001  NCT03884101 A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001) S. Ghamande Donna Wheatley Endometrial Cancer III